TFP
AVXL icon

Tilia Fiduciary Partners’s Anavex Life Sciences AVXL Stock Holding History

Tilia Fiduciary Partners’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-215
Closed -$3K – 508
2022
Q2 		$3K Hold
215
– – ﹤0.01% 466
2022
Q1 		$3K Hold
215
– – ﹤0.01% 491
2021
Q4 		$4K Buy
+215
New +$4.08K ﹤0.01% 493

Other funds holding AVXL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
PC
Pier Capital Stamford, Connecticut $755M AUM 94.38% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Tilia Fiduciary Partners's AVXL Position: Q3 2022 in Review

Tilia Fiduciary Partners sold out of Anavex Life Sciences (AVXL) in Q3 2022, closing a stake of 215 shares — an estimated $3K sold.

Tilia Fiduciary Partners first reported a position in AVXL in Q4 2021 and held it in 3 quarters. The position peaked at $4K in Q4 2021. 147 funds tracked by Wall St. Rank hold AVXL as of Q3 2022.

  • Tilia Fiduciary Partners reported no remaining Anavex Life Sciences position as of Q3 2022 after selling out during the quarter.
  • Tilia Fiduciary Partners sold 215 Anavex Life Sciences shares in Q3 2022, an estimated $3K.
  • Tilia Fiduciary Partners first reported a position in Anavex Life Sciences in Q4 2021 and held it in 3 quarters.
  • Tilia Fiduciary Partners's Anavex Life Sciences position peaked at $4K in Q4 2021.
  • 147 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q3 2022.

Based on Tilia Fiduciary Partners's 13F filing for Q3 2022, filed 27 Oct 2022.